Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CENPE | Q02224 | 3/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.36 |
| ▸ | RELA | Q04206 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2106962 | 1.00 | CENPE (0.85) | CENPEKDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL3462519 | 0.93 | CENPE (0.85) | CENPEKDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL13161478 | 0.93 | CENPE (0.85) | CENPEKDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL3462400 | 0.92 | CENPE (0.73) | CENPEKDM4EALDH1A1KMT2AMAPT | |
| SCHEMBL13161626 | 0.92 | CENPE (0.73) | CENPEKDM4EALDH1A1KMT2AMAPT | |
| Gsk-923295A SCHEMBL2101077 | 0.92 | CENPE (1.00) | CENPEKDM4EALDH1A1KMT2AMAPT | |
| Gsk-923295A SCHEMBL1492164 | 0.92 | CENPE (1.00) | CENPEKDM4EALDH1A1KMT2AMAPT | |
| Gsk-923295A SCHEMBL29379288 | 0.92 | CENPE (1.00) | CENPEKDM4EALDH1A1KMT2AMAPT | |
| Gsk-923295A SCHEMBL368558 | 0.92 | CENPE (1.00) | CENPEKDM4EALDH1A1KMT2AMAPT | |
| Gsk-923295A SCHEMBL10215273 | 0.92 | CENPE (1.00) | CENPEKDM4EALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582682-B1 | MITOTIC KINESIN INHIBITORS FOR USE IN THE TREATMETNOF PULMONARY ARTERIAL HYPERTENSION | CYTOKINETICS INC (US) | 2015-01-14 | — | — | EP | claimed |
| US-20130210733-A1 | METHODS OF TREATING LUNG DISEASE | CYTOKINETICS, INC. | 2013-08-15 | — | — | US | claimed |
| EP-2582682-A1 | METHODS OF TREATING LUNG DISEASE | Cytokinetics, Inc. (US) | 2013-04-24 | — | — | EP | claimed |
| WO-2012009097-A1 | METHODS OF TREATING LUNG DISEASE | CYTOKINETICS, INC. (US) | 2012-01-19 | — | — | WO | claimed |
| US-7504413-B2 | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases | CYTOKINETICS, INC. (US) | 2009-03-17 | — | — | US | claimed |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2008-10-16 | — | — | US | claimed |
| EP-2582682-B1 | MITOTIC KINESIN INHIBITORS FOR USE IN THE TREATMETNOF PULMONARY ARTERIAL HYPERTENSION | CYTOKINETICS INC (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8772507-B2 | Imidazole-benzamide anti-cancer agents | CYTOKINETICS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130210733-A1 | METHODS OF TREATING LUNG DISEASE | CYTOKINETICS, INC. | 2013-08-15 | — | — | US | disclosed |
| EP-2582682-A1 | METHODS OF TREATING LUNG DISEASE | Cytokinetics, Inc. (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | QIAN XIANGPING (US) | 2013-04-18 | — | — | US | disclosed |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-11-08 | — | — | US | disclosed |
| WO-2012009097-A1 | METHODS OF TREATING LUNG DISEASE | CYTOKINETICS, INC. (US) | 2012-01-19 | — | — | WO | disclosed |
| EP-1742907-A4 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-08-23 | — | — | US | disclosed |
| CN-101023057-A | Certain chemicals, compositions, and methods | CYTOKINETICS INC (US) | 2007-08-22 | — | — | CN | disclosed |
| EP-1742907-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-11-02 | — | — | US | disclosed |
| US-20060094708-A1 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INCORPORATED | 2006-05-04 | — | — | US | disclosed |
| WO-2005107762-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094708-A1 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | KIF5B, KIF18A, KIF2C | CENPE 522/4885KDM4E 962/4885ALDH1A1 1729/4885 |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CENPE 54/4885KDM4E 3267/4885ALDH1A1 2159/4885 |
| US-20080255182-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CENPE 54/4885KDM4E 3267/4885ALDH1A1 2159/4885 |
| US-20120283287-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIF5B, KIF2C, PLK1 | CENPE 54/4885KDM4E 3267/4885ALDH1A1 2159/4885 |
| US-20130096315-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | KIF5B, KIF2C, PLK1 | CENPE 50/4885KDM4E 3116/4885ALDH1A1 1977/4885 |
| US-20070197481-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | CENPE 54/4885KDM4E 3267/4885ALDH1A1 2159/4885 |
| US-20130210733-A1 | METHODS OF TREATING LUNG DISEASE | KIF5B, KIF2C, KIF18B | CENPE 70/4885KDM4E 2636/4885ALDH1A1 2283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.